Potential Novel Biomarkers for Chronic Lung Allograft Dysfunction and Azithromycin Responsive Allograft Dysfunction

Overview

Journal Sci Rep

Specialty Science

Date 2021 Mar 25

PMID 33762606

Citations 8

Authors

Cecilia Veraar

Jonathan Kliman

Alberto Benazzo

Felicitas Oberndorfer

Maria Laggner

Philipp Hacker

Thomas Raunegger

Stefan Janik

Peter Jaksch

Walter Klepetko

Hendrik J Ankersmit

Bernhard Moser

Affiliations

Soon will be listed here.

Abstract

Chronic Lung Allograft Dysfunction (CLAD), manifesting as Bronchiolitis Obliterans Syndrome (BOS) or Restrictive Allograft Syndrome (RAS), is the main reason for adverse long-term outcome after Lung Transplantation (LTX). Until now, no specific biomarkers exist to differentiate between CLAD phenotypes. Therefore, we sought to find suitable cytokines to distinguish between BOS, RAS and Azithromycin Responsive Allograft Dysfunction (ARAD); and reveal potential similarities or differences to end-stage fibrotic diseases. We observed significantly increased Lipocalin-2 serum concentrations in RAS compared to BOS patients. In addition, in RAS patients immunohistochemistry revealed Lipocalin-2 expression in bronchial epithelium and alveolar walls. Patients with ARAD showed significantly lower Activin-A serum concentrations compared to Stable-LTX and BOS patients. Further, increased serum concentrations of Lipocalin-2 and Activin-A were predictors of worse freedom-from-CLAD in Stable-LTX patients. These biomarkers serve as promising serum biomarkers for CLAD prediction and seem suitable for implementation in clinical practice.

Citing Articles

Late-Onset Exudative Pleural Effusions Without Concomitant Airway Obstruction or Lung Parenchymal Abnormalities: A Novel Presentation of Chronic Lung Allograft Dysfunction.

Sindu D, Bansal S, Buddhdev B, McAnally K, Mohamed H, Walia R Transpl Int. 2024; 37:12395.

PMID: 38357217 PMC: 10866027. DOI: 10.3389/ti.2024.12395.

Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients.

Ju C, Xu X, Zhang J, Chen A, Lian Q, Liu F BMC Pulm Med. 2023; 23(1):37.

PMID: 36703125 PMC: 9881379. DOI: 10.1186/s12890-022-02229-y.

Molecular Profiling of Tissue Samples with Chronic Rejection from Patients with Chronic Lung Allograft Dysfunction: A Pilot Study in Cystic Fibrosis Patients.

Lunardi F, Abbrescia D, Vedovelli L, Pezzuto F, Fortarezza F, Comacchio G Biomolecules. 2023; 13(1).

PMID: 36671482 PMC: 9856133. DOI: 10.3390/biom13010097.

Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective.

Cavallaro D, Guerrieri M, Cattelan S, Fabbri G, Croce S, Armati M Biomedicines. 2022; 10(12).

PMID: 36552035 PMC: 9775233. DOI: 10.3390/biomedicines10123277.

Genetic Deletion of Does Not Reduce Airway Inflammation and Structural Lung Damage in Mice with Cystic Fibrosis-like Lung Disease.

Wagner C, Balazs A, Schatterny J, Zhou-Suckow Z, Duerr J, Schultz C Int J Mol Sci. 2022; 23(21).

PMID: 36362203 PMC: 9657231. DOI: 10.3390/ijms232113405.

References

Meyer K, Raghu G, Verleden G, Corris P, Aurora P, Wilson K . An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014; 44(6):1479-503. DOI: 10.1183/09031936.00107514. View

Castellani S, Di Gioia S, di Toma L, Conese M . Human Cellular Models for the Investigation of Lung Inflammation and Mucus Production in Cystic Fibrosis. Anal Cell Pathol (Amst). 2018; 2018:3839803. PMC: 6276497. DOI: 10.1155/2018/3839803. View

Hardy C, King S, Mifsud N, Hedger M, Phillips D, Mackay F . The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology. Immunol Cell Biol. 2015; 93(6):567-74. PMC: 4495664. DOI: 10.1038/icb.2015.7. View

Sato M, Hwang D, Waddell T, Singer L, Keshavjee S . Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant. 2012; 32(1):23-30. DOI: 10.1016/j.healun.2012.09.026. View

Redl B, Wojnar P, Ellemunter H, Feichtinger H . Identification of a lipocalin in mucosal glands of the human tracheobronchial tree and its enhanced secretion in cystic fibrosis. Lab Invest. 1998; 78(9):1121-9. View

Walshaw M . Cystic fibrosis: Diagnosis and management - NICE guideline 78. Paediatr Respir Rev. 2019; 31:12-14. DOI: 10.1016/j.prrv.2019.02.006. View

Karagiannidis C, Hense G, Martin C, Epstein M, Ruckert B, Mantel P . Activin A is an acute allergen-responsive cytokine and provides a link to TGF-beta-mediated airway remodeling in asthma. J Allergy Clin Immunol. 2006; 117(1):111-8. DOI: 10.1016/j.jaci.2005.09.017. View

Cowland J, Sorensen O, Sehested M, Borregaard N . Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol. 2003; 171(12):6630-9. DOI: 10.4049/jimmunol.171.12.6630. View

Ikezoe K, Handa T, Mori K, Watanabe K, Tanizawa K, Aihara K . Neutrophil gelatinase-associated lipocalin in idiopathic pulmonary fibrosis. Eur Respir J. 2014; 43(6):1807-9. DOI: 10.1183/09031936.00192613. View

10.

Bystrzycka W, Manda-Handzlik A, Sieczkowska S, Moskalik A, Demkow U, Ciepiela O . Azithromycin and Chloramphenicol Diminish Neutrophil Extracellular Traps (NETs) Release. Int J Mol Sci. 2018; 18(12). PMC: 5751268. DOI: 10.3390/ijms18122666. View

11.

Dittrich A, Meyer H, Hamelmann E . The role of lipocalins in airway disease. Clin Exp Allergy. 2013; 43(5):503-11. DOI: 10.1111/cea.12025. View

12.

Fernandez I, Heinzelmann K, Verleden S, Eickelberg O . Characteristic patterns in the fibrotic lung. Comparing idiopathic pulmonary fibrosis with chronic lung allograft dysfunction. Ann Am Thorac Soc. 2015; 12 Suppl 1:S34-41. DOI: 10.1513/AnnalsATS.201410-476MG. View

13.

Fernandez I, Eickelberg O . New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012; 380(9842):680-8. DOI: 10.1016/S0140-6736(12)61144-1. View

14.

Janik S, Schiefer A, Bekos C, Hacker P, Haider T, Moser J . HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications. Sci Rep. 2016; 6:24267. PMC: 4838882. DOI: 10.1038/srep24267. View

15.

Sato M, Waddell T, Wagnetz U, Roberts H, Hwang D, Haroon A . Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011; 30(7):735-42. DOI: 10.1016/j.healun.2011.01.712. View

16.

Hedger M, de Kretser D . The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 2013; 24(3):285-95. DOI: 10.1016/j.cytogfr.2013.03.003. View

17.

Kennedy V, Todd J, Palmer S . Bronchoalveolar lavage as a tool to predict, diagnose and understand bronchiolitis obliterans syndrome. Am J Transplant. 2013; 13(3):552-61. PMC: 3582805. DOI: 10.1111/ajt.12091. View

18.

Lagente V, Boichot E . Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J Mol Cell Cardiol. 2009; 48(3):440-4. DOI: 10.1016/j.yjmcc.2009.09.017. View

19.

Nishikawa T, Inomata S, Igarashi M, Goyagi T, Naito H . Plasma lidocaine concentrations during epidural blockade with isoflurane or halothane anesthesia. Anesth Analg. 1992; 75(6):885-8. DOI: 10.1213/00000539-199212000-00004. View

20.

Pain M, Royer P, Loy J, Girardeau A, Tissot A, Lacoste P . T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase-9 via a C-C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft Dysfunction. Am J Transplant. 2016; 17(6):1502-1514. DOI: 10.1111/ajt.14166. View